D.E. Shaw & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

D.E. Shaw & Co’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-40,000	Closed	-$1.15M	–	3247
2016 Q4	$1.15M	Hold	40,000	–	–	﹤0.01%	2375
2016 Q3	$1.27M	Hold	40,000	–	–	﹤0.01%	2236
2016 Q2	$1.3M	Hold	40,000	–	–	﹤0.01%	2241
2016 Q1	$1.12M	Buy	+40,000	New	+$872K	﹤0.01%	2285
2015 Q1	–	Sell	-43,800	Closed	-$1.39M	–	3585
2014 Q4	$1.39M	Hold	43,800	–	–	﹤0.01%	2570
2014 Q3	$1.08M	Sell	43,800 -6,200	-12%	-$145K	﹤0.01%	2728
2014 Q2	$1.13M	Sell	50,000 -15,000	-23%	-$313K	﹤0.01%	2826
2014 Q1	$1.58M	Sell	65,000 -61,900	-49%	-$1.57M	﹤0.01%	2614
2013 Q4	$3.17M	Hold	126,900	–	–	﹤0.01%	2077
2013 Q3	$3.49M	Buy	126,900 +51,900	+69%	+$1.08M	0.01%	1926
2013 Q2	$1.36M	Buy	+75,000	New	+$1.03M	﹤0.01%	2457

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

D.E. Shaw & Co's ACAD Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Acadia Pharmaceuticals (ACAD) stake by 29% in Q1 2026, selling an estimated $7.1M and leaving 729,836 shares worth $16.2M. The position accounts for 0.01% of the portfolio, ranked #1281.

D.E. Shaw & Co first reported a position in ACAD in Q2 2013 and has held it in 48 quarters since. The position peaked at $126M in Q2 2023. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

D.E. Shaw & Co held 729,836 shares of Acadia Pharmaceuticals worth $16.2M as of Q1 2026.
D.E. Shaw & Co sold 296,949 Acadia Pharmaceuticals shares in Q1 2026, an estimated $7.1M.
Acadia Pharmaceuticals made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1281 holding.
D.E. Shaw & Co first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
D.E. Shaw & Co's Acadia Pharmaceuticals position peaked at $126M in Q2 2023.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.